Trump Administration Boosts FDA Funding for Infant Formula Modernization in FY2027
Event summary
- The Trump Administration's FY2027 budget request includes a $108.5 million increase for FDA's Human Foods Program, targeting infant formula regulation.
- FDA's Priority Deliverables for 2026 now include infant formula, signaling heightened regulatory focus.
- Updated Protein Efficiency Ratio (PER) guidance for plant-based formulas is expected to be finalized in 2026.
- Else Nutrition, a plant-based infant formula pioneer, stands to benefit from these regulatory shifts.
The big picture
The Trump Administration's increased funding for infant formula regulation reflects a broader industry shift toward plant-based alternatives. This move aligns with growing consumer demand for non-dairy, non-soy options and could reshape the competitive landscape. Else Nutrition, positioned as a leader in plant-based formulas, may see significant strategic advantages as regulatory pathways become clearer.
What we're watching
- Regulatory Clarity
- How the finalization of PER guidance will impact plant-based formula approvals and market entry.
- Market Expansion
- Whether increased FDA funding will accelerate the adoption of plant-based infant formulas.
- Competitive Dynamics
- The pace at which traditional dairy-based formula companies adapt to new regulatory standards.
Our editorial coverage: